Literature DB >> 25291660

Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.

Dick C Chan1, Annette T Y Wong1, Jing Pang1, P Hugh R Barrett1, Gerald F Watts1.   

Abstract

Postprandial lipaemia, due to elevated plasma apolipoprotein (apo) B-48 concentrations, contributes to increased cardiovascular (CV) risk in obesity. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and apoC-III may play a role in regulating triacylglycerol-rich lipoprotein (TRL)-apoB-48 metabolism. We investigated the associations between plasma PCSK9 and apoC-III concentrations and the kinetics of apoB-48 in obese subjects. Seventeen obese subjects were given an oral fat load. ApoB-48 tracer/tracee ratios were measured after an intravenous 2H3-leucine administration using GC-MS. Kinetic parameters, including secretion and fractional catabolic rates (FCRs), were derived using a multi-compartmental model. Plasma PCSK9 and apoC-III concentrations were significantly and positively (P<0.05 in all) associated with the total area-under-curve (AUC) and incremental AUC for apoB-48 and inversely with TRL-apoB-48 FCR. Plasma PCSK9 and apoC-III concentrations were not correlated (P>0.05 in all) with basal secretion or the number of TRL-apoB-48 secreted over the postprandial period. In the stepwise regression analysis, plasma PCSK9 was the best predictor of the total and incremental AUCs for plasma apoB-48 and the FCR of TRL-apoB-48. The association between plasma PCSK9 and apoC-III and TRL-apoB-48 FCR remained significant (P<0.05 in all) after adjusting for age, homoeostasis model assessment (HOMA) score, hepatic lipase or lipoprotein lipase (LPL). In a multiple regression model, 31% of variance in TRL-apoB-48 FCR was accounted for by plasma PCSK9 and apoC-III concentrations (adjusted R2=0.306, P<0.05). However, their associations with TRL-apoB-48 FCR were not independent of each other. Our results suggest that the catabolism of TRL-apoB-48 in the postprandial state may be co-ordinated by PCSK9 and apoC-III in obese individuals.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25291660     DOI: 10.1042/CS20140559

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  15 in total

1.  Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance.

Authors:  Jean-Philippe Drouin-Chartier; André J Tremblay; Jean-Charles Hogue; Valéry Lemelin; Benoît Lamarche; Patrick Couture
Journal:  J Lipid Res       Date:  2018-06-26       Impact factor: 5.922

2.  Oestrogen-modulated gene expression in the human endometrium.

Authors:  C Punyadeera; H Dassen; J Klomp; G Dunselman; R Kamps; F Dijcks; A Ederveen; A de Goeij; P Groothuis
Journal:  Cell Mol Life Sci       Date:  2005-01       Impact factor: 9.261

Review 3.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.

Authors:  Nicola Ferri; Massimiliano Ruscica
Journal:  Endocrine       Date:  2016-04-01       Impact factor: 3.633

Review 4.  [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].

Authors:  J Thiery; R Burkhardt
Journal:  Herz       Date:  2016-06       Impact factor: 1.443

5.  Identification of proteins associated with pediatric bilateral Wilms tumor.

Authors:  Zechen Yan; Qingjun Meng; Jinjian Yang; Junjie Zhang; Wei Zhao; Fei Guo; Dongjian Song; Yuxiao Zhan; Dandan Fan; Ruiyi Zhou; Shuqiang Zuo; Zehua Wang; Jiekai Yu; Shu Zheng; Jiaxiang Wang
Journal:  Oncol Lett       Date:  2016-10-21       Impact factor: 2.967

6.  The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels.

Authors:  Jean-Philippe Drouin-Chartier; Jean-Charles Hogue; André J Tremblay; Jean Bergeron; Benoît Lamarche; Patrick Couture
Journal:  Lipids Health Dis       Date:  2017-06-15       Impact factor: 3.876

7.  Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.

Authors:  Dick C Chan; Gerald F Watts; Ransi Somaratne; Scott M Wasserman; Rob Scott; P Hugh R Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-06-07       Impact factor: 8.311

8.  Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics.

Authors:  E Björnson; C J Packard; M Adiels; L Andersson; N Matikainen; S Söderlund; J Kahri; C Sihlbom; A Thorsell; H Zhou; M-R Taskinen; J Borén
Journal:  J Intern Med       Date:  2019-03-12       Impact factor: 8.989

Review 9.  PCSK9 and triglyceride-rich lipoprotein metabolism.

Authors:  I Druce; H Abujrad; T C Ooi
Journal:  J Biomed Res       Date:  2015-07-20

10.  Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population.

Authors:  Wen Guo; Yingyun Gong; Yong Gu; Zhenzhen Fu; Hongqi Fan; Beibei Gao; Xiaohui Zhu; Jinxiang Fu; Yang Zhao; Min Sun; Xing Liu; Xian-Cheng Jiang; Tao Yang; Hongwen Zhou
Journal:  Lipids Health Dis       Date:  2018-01-17       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.